InsidersTradesSigma
Follow the Kiniksa Pharmaceuticals, Ltd. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Health Care sector, Kiniksa Pharmaceuticals, Ltd. has published 83 public disclosures. Market capitalisation: €4.9bn. The latest transaction was reported on 7 June 2024 (Levée d'options). Among the most active insiders: Megna Michael R. All data is openly available.
83
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€1m
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Kiniksa Pharmaceuticals, Ltd. Strong Buy (bullish), based on 8 analysts. Average price target: US$68.13.
41Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,217 of 29,055 companies
60.6
score / 100
Value45
Quality76
FCF yld2.2%
Earn yld1.0%
EV/EBITDA·
ROE14%
Gross mgn55%
Net mgn8.7%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 7 June 2024
Declarations83 total
4,373 sharesClass A Common ShareSEC:0001415889-24-015997:0
4,373 sharesClass A Common ShareSEC:0001415889-24-016009:0
4,373 sharesClass A Common SharesSEC:0001415889-24-016002:0
4,373 sharesClass A Common ShareSEC:0001415889-24-016006:0
4,373 sharesClass A Common ShareSEC:0001415889-24-015994:0
4,373 sharesClass A Common ShareSEC:0001415889-24-016000:0
6,346 shares0Class A Common SharesSEC:0000950170-24-070612:0
747 sharesClass A Common ShareSEC:0001415889-24-012480:0
991 sharesClass A Common ShareSEC:0001415889-24-011764:0
2,694 sharesClass A Common ShareSEC:0001415889-24-010509:0
3,932 sharesClass A Common ShareSEC:0001415889-24-010505:0
2,497 sharesClass A Common ShareSEC:0001415889-24-010511:0
2,726 sharesClass A Common ShareSEC:0001415889-24-010503:0
9,992 sharesClass A Common ShareSEC:0001415889-24-010514:0
6,482 sharesClass A Common ShareSEC:0001415889-24-010086:0
2,558 sharesClass A Common ShareSEC:0001415889-24-010084:0
1,750 sharesClass A Common ShareSEC:0001415889-24-010091:0
1,773 sharesClass A Common ShareSEC:0001415889-24-010088:0
1,624 sharesClass A Common ShareSEC:0001415889-24-010077:0
65,012 shares@ US$21.0287.2% of flowClass A Common ShareSEC:0001415889-24-007569:0
9,406 shares@ US$21.3112.8% of flowClass A Common ShareSEC:0001415889-24-007083:0
656 shares@ US$1.595.0% of flowClass A Common ShareSEC:0001415889-24-006702:0
18,844 shares@ US$1.8616.1% of flowClass A Common ShareSEC:0001415889-24-006674:0
25 of 83 declarations
Acerca de Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos para enfermedades inmunológicas e inflamatorias. Cotiza en NASDAQ bajo el ticker KNSA.